P173 Prevalence of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada — A multicenter survey of 2001 patients

Gupta, Abhaya; Jain, Hem C.; Lynde, Charles; Watteel, G.N.; Summerbell, Richard C.

doi:10.1016/s0926-9959(97)89647-x

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16][17] The prevalence in North America is 4.3% in Canada and 20% in the United States, whereas in South America 4.5 and 9.5% in two different centers in Colombia and 1% in Argentina. [18][19][20][21] Tosti performed a mycological study on 1548 patients affected by nail disorders and diagnosed 431 cases of onychomycosis out of which 59 were caused by moulds. 22 These included 17 patients caused by Scopulariopsis berviacaulis, Fusarium in 26, Acremonium in 9 and 7 patients were caused by Aspergillus species.…”

Section: Discussionmentioning

confidence: 99%

Onychomycosis: role of non dermatophytes

Narain¹,

Bajaj

2016

Int J Adv Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Onychomycosis: role of non dermatophytes

Narain¹,

Bajaj

2016

Int J Adv Med

View full text Add to dashboard Cite

“…The prevalence of onychomycosis in the North American adult population may range from 2% to 18%, with prevalence increasing to 20% and 30% for those older than 60 years and 70 years, respectively. [1][2][3][4][5] Onychomycosis is commonly associated with tinea pedis. Significant physical and psychological effects, such as pain and negative self-image, may occur in patients with onychomycosis.…”

mentioning

confidence: 99%

Novel Treatment of Onychomycosis using Over-the-Counter Mentholated Ointment: A Clinical Case Series

Derby¹,

Rohal²,

Jackson³

et al. 2011

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Ciclopirox nail lacquer and podiatric practice

Gupta

Malkin

2000

Journal of the American Podiatric Medical Association

View full text Add to dashboard Cite

Ciclopirox 8% nail lacquer has recently been approved by the US Food and Drug Administration (FDA) for the management of mild-to-moderate dermatophytic onychomycosis not involving the lunula. Previously, the agents that were approved for the treatment of dermatophytic pedal onychomycosis--griseofulvin, itraconazole, and terbinafine--were administered orally. When ciclopirox nail lacquer is used, it is recommended that the infected nail undergo debridement by a health-care professional as frequently as monthly. It is important to be aware of the circumstances under which debridement of the mycotic nail may be considered medically necessary and therefore potentially eligible for reimbursement by third-party payers. For many nail presentations, nail debridement is an important component of a treatment protocol involving either the oral medications or the topical lacquer, as it serves to reduce the fungal load and ameliorate symptoms. With the availability of a new FDA-approved topical treatment alternative, it remains to be seen if podiatrists will embrace the definitive treatment of onychomycosis using the newer oral agents, the new nail lacquer, or both in combination with nail debridement to treat the disease.

show abstract

P173 Prevalence of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada — A multicenter survey of 2001 patients

Cited by 3 publications

References 0 publications

Onychomycosis: role of non dermatophytes

Onychomycosis: role of non dermatophytes

Novel Treatment of Onychomycosis using Over-the-Counter Mentholated Ointment: A Clinical Case Series

Ciclopirox nail lacquer and podiatric practice

Contact Info

Product

Resources

About